Evidence map›Paper›PMID 39042403›Full record

ArticleInvestigative ophthalmology & visual science2024

Protein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status.

Maria Chiara Gelmi, Arnoud H de Ru, Peter A van Veelen, Rayman T N Tjokrodirijo, Marc-Henri Stern, Alexandre Houy, Robert M Verdijk, T H Khanh Vu, Bruce R Ksander, Jolanda Vaarwater and 3 more

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Topotecan Synergizes with SP141 in the Management of Uveal Melanoma.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. The latestExpert opinion on drug discovery · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maria Chiara GelmiDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Arnoud H de RuCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Peter A van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Rayman T N TjokrodirijoCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Marc-Henri SternInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, PSL Research University, Paris, France.
Alexandre HouyInserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, PSL Research University, Paris, France.
Robert M VerdijkDepartment of Pathology, Ophthalmic Pathology Section, Erasmus MC, Rotterdam, The Netherlands.
T H Khanh VuDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Bruce R KsanderSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States.
Jolanda VaarwaterDepartment of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Emine KilicDepartment of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.
Erwin BrosensDepartment of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Martine J JagerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Cell lines are being used in preclinical uveal melanoma (UM) research. Because not all cell lines harbor typical GNAQ or GNA11 hotspot mutations, we aimed at better classifying them and determining whether we could find genetic causes to explain the protein and mRNA expression profiles of the cell lines. Methods: We studied protein and mRNA expression of 14 UM cell lines and determined the presence of single nucleotide variants and small insertions and deletions with next-generation sequencing and copy number alterations with a single nucleotide polymorphism array. The lists of differentially expressed proteins and genes were merged, and shared lists were created, keeping only terms with concordant mRNA and protein expression. Enrichment analyses were performed on the shared lists. Results: Cell lines Mel285 and Mel290 are separate from GNA-mutated cell lines and show downregulation of melanosome-related markers. Both lack typical UM mutations but each harbors four putatively deleterious variants in CTNNB1, PPP1R10, LIMCH1, and APC in Mel285 and ARID1A, PPP1R10, SPG11, and RNF43 in Mel290. The upregulated terms in Mel285 and Mel290 did not point to a convincing alternative origin. Mel285 shows loss of chromosomes 1p, 3p, partial 3q, 6, and partial 8p, whereas Mel290 shows loss of 1p and 6. Expression in the other 12 cell lines was related to BAP1 expression. Conclusions: Although Mel285 and Mel290 have copy number alterations that fit UM, multi-omics analyses show that they belong to a separate group compared to the other analyzed UM cell lines. Therefore, they may not be representative models to test potential therapeutic targets for UM.

Indexed as

Gene Expression Regulation, NeoplasticGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11MelanomaMutationRNA, MessengerTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal NeoplasmsCell Line, TumorDNA Copy Number VariationsDNA Mutational AnalysisHumansPolymorphism, Single NucleotideUveal MelanomaBAP1 protein, humanGNA11 protein, humanGNAQ protein, humanGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11RNA, MessengerTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID39042403
PMCPMC11268447

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.